‘National Interest’ PRV Program Raises Concerns Over FDA Resources

FDA’s new “Commissioner’s National Priority Review Voucher” (CNPRV) program, which promises to slash drug review timelines to as little as one to two months for selected companies promising to advance national priorities, is drawing mixed reactions from industry experts, who tell Inside Health Policy the effort to speed reviews for select high-priority drugs could intensify pressure on an already overstretched agency grappling with growing application backlogs.